Compare Advanced Micro Devices (AMD) vs Biogen Inc (BIIB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advanced Micro Devices vs Biogen Inc — how do they compare? Advanced Micro Devices trades at $543.4 (market cap $909.70B), while Biogen Inc trades at $203.64 (market cap $29.40B). The key difference: Advanced Micro Devices is far larger — about 30.9× Biogen Inc's market cap. Which is the better fit depends on your goals.
| AMD | BIIB | |
|---|---|---|
Market Cap | $909.70B | $29.40B |
Sector | Technology | Health |
52-Week High | $580.91 | $216.63 |
52-Week Low | $146.24 | $122.68 |
Enterprise Value | $901.22B | $31.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today, approaching its 52-week high amid strong AI-driven momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth, reaching $34.64B in 2025. Analyst sentiment remains overwhelmingly positive with a 71.43% buy rating, though valuation metrics like a P/E of 185.96 indicate premium pricing. Cash flow from operations surged to $7.71B in 2025, supporting aggressive investment in AI infrastructure.
Outlook: AMD is well-positioned to capitalize on AI and data center demand, but high valuation and intense competition pose risks. Investors should weigh growth potential against premium multiples, with the consensus price target of $508.24 suggesting near-term caution despite long-term optimism.
Biogen (BIIB) trades at $199.15, up 0.12% on the day, with a bullish technical signal from moving averages and RSI near oversold levels at 20.73. The company reported Q1 2026 EPS of $3.57, beating estimates of $3.05, continuing a trend of earnings surprises. Revenue for 2025 was $9.89B with a net income margin of 13.81%, while recent acquisitions like RayThera for up to $1B aim to bolster its immunology pipeline. Analyst consensus price target is $226.00, implying potential upside from current levels.
BIIB presents a mixed outlook with strong earnings momentum and strategic acquisitions offset by legacy drug sales declines and legal investigations. The stock's valuation at a P/E of 21.41 is reasonable relative to growth prospects, but investors face risks from pipeline execution and competitive pressures in biotech. Near-term catalysts include Alzheimer's data presentations at AAIC 2026 in July.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
